These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9058744)

  • 41. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo.
    Johnson BD; Truitt RL
    Transplantation; 1992 Jul; 54(1):104-12. PubMed ID: 1631918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Graft-vs-host reactions (GVHR) across minor murine histocompatibility barriers. II. Development of natural suppressor cell activity.
    Maier T; Holda JH; Claman HN
    J Immunol; 1985 Sep; 135(3):1644-51. PubMed ID: 3160774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease.
    Serody JS; Burkett SE; Panoskaltsis-Mortari A; Ng-Cashin J; McMahon E; Matsushima GK; Lira SA; Cook DN; Blazar BR
    Blood; 2000 Nov; 96(9):2973-80. PubMed ID: 11049973
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Donor CD8+ T cells mediate graft-versus-leukemia activity without clinical signs of graft-versus-host disease in recipients conditioned with anti-CD3 monoclonal antibody.
    Zhang C; Lou J; Li N; Todorov I; Lin CL; Cao YA; Contag CH; Kandeel F; Forman S; Zeng D
    J Immunol; 2007 Jan; 178(2):838-50. PubMed ID: 17202345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation.
    Drobyski WR; Gendelman M; Vodanovic-Jankovic S; Gorski J
    J Immunol; 2003 Mar; 170(6):3046-53. PubMed ID: 12626559
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
    Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
    Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning.
    Kim YM; Mapara MY; Down JD; Johnson KW; Boisgerault F; Akiyama Y; Benichou G; Pelot M; Zhao G; Sykes M
    Blood; 2004 Jan; 103(2):732-9. PubMed ID: 14512313
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation.
    Korngold R; Leighton C; Manser T
    Transplantation; 1994 Aug; 58(3):278-87. PubMed ID: 7914387
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice.
    Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S
    Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors.
    Christianson SW; Shultz LD; Leiter EH
    Diabetes; 1993 Jan; 42(1):44-55. PubMed ID: 8093606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells.
    Yang YG; Qi J; Wang MG; Sykes M
    Blood; 2002 Jun; 99(11):4207-15. PubMed ID: 12010827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Graft-versus-leukemia effect in MHC-compatible and -incompatible allogeneic bone marrow transplantation of radiation-induced, leukemia-bearing mice.
    Aizawa S; Sado T
    Transplantation; 1991 Nov; 52(5):885-9. PubMed ID: 1949175
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.
    Lu L; Li W; Fu F; Chambers FG; Qian S; Fung JJ; Thomson AW
    Transplantation; 1997 Dec; 64(12):1808-15. PubMed ID: 9422424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
    Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
    Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alloreactive and leukemia-reactive T cells are preferentially derived from naive precursors in healthy donors: implications for immunotherapy with memory T cells.
    Distler E; Bloetz A; Albrecht J; Asdufan S; Hohberger A; Frey M; Schnürer E; Thomas S; Theobald M; Hartwig UF; Herr W
    Haematologica; 2011 Jul; 96(7):1024-32. PubMed ID: 21486863
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in AKR mice with spontaneous leukemia/lymphoma.
    Truitt RL; Shih CC; LeFever AV
    Transplantation; 1986 Mar; 41(3):301-10. PubMed ID: 3513389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.